• YOU ARE AT |
  • Home
  • News
  • Biosidus at ECTRIMS 2016

New Technologies/ view all

  • Transgenic animals to produce therapeutic proteins

    Biosidus has concluded is working on novel technologies for high-yield and cost-effective production of recombinant proteins for pharmaceutical applications.

  • Gene Therapy

    Angiogenesis and muscle regeneration using the vascular endothelial growth factor.
    Vascular endothelial growth factor (VEGF) is a protein that stimulates the growth of blood vessels.

  • Biodiversity

    White Genome Project
    Yet another groundbreaking initiative for Biosidus is the White Genome Project, which aims to isolate, identify and characterize Antarctic bacterial strains for further sequencing of the complete genome.


Biosidus at ECTRIMS 2016

The European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) has been gathering the world’s most eminent global MS experts on a yearly basis. This year, London (UK) will host ECTRIMS 2016 in September 14-16.

This is the fourth ECTRIMS edition having Biosidus S.A. as outstanding exhibitor of the Argentine Biotechnology. Blastoferon® (interferon beta 1a) is Biosidus’s remarkable R&D contribution to the Multiple Sclerosis immunomodulating therapy showing its commitment to the treatment of this disabling disease which affects more than 8000 patients solely in Argentina. We will be glad to meet you in our booth #E20.